Clinical Trials Logo

Clinical Trial Summary

RATIONALE: Alpha-lipoic acid may prevent or lessen hearing loss caused by cisplatin.

PURPOSE: This randomized clinical trial is studying the effectiveness of alpha-lipoic acid in preventing hearing loss in cancer patients undergoing treatment with cisplatin.


Clinical Trial Description

OBJECTIVES:

Primary

Determine the ability of alpha-lipoic acid supplementation to prevent or reduce the incidence and severity of hearing loss in cancer patients undergoing treatment with cisplatin.

Secondary

Determine if this drug improves the oxidative state, as measured by a malondialdehyde measurement of oxidative stress, thereby protecting the patient against ototoxic-induced hearing loss.

OUTLINE: This is a placebo-controlled, double-blind, randomized, multicenter study. Patients are stratified by cancer stage and institution. Patients are randomized to 1 of 2 treatment arms.

Arm I: Patients receive oral alpha-lipoic acid supplement once a day beginning 1 week before the start of cisplatin treatment and continuing for up to 1 month after the completion of cisplatin. During cisplatin treatment, patients discontinue supplement 1 day prior to the cisplatin treatment and resume daily supplements 2 days post treatment.

Arm II: Patients receive oral placebo supplement once a day beginning 1 week before the start of cisplatin and continuing for up to 1 month after the completion of cisplatin. During cisplatin treatment, patients discontinue supplement 1 day prior to the cisplatin treatment and resume daily supplements 2 days post treatment.

Hearing and ototoxicity are assessed at baseline, on each day of chemotherapy, and at 1 and 3 months post chemotherapy.

Blood samples are collected periodically to measure malondialdehyde and alpha-lipoic acid levels.

After completion of treatment with cisplatin, patients are followed for 3 months. ;


Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care


Related Conditions & MeSH terms


NCT number NCT00477607
Study type Interventional
Source VA Office of Research and Development
Contact
Status Completed
Phase Phase 2/Phase 3
Start date October 2007
Completion date June 2011

See also
  Status Clinical Trial Phase
Recruiting NCT01624324 - Aminoglycoside Plasma Level Measurement in Neonates With Infection N/A
Completed NCT00458887 - Assessing Ear Damage in Young Cancer Patients Treated With Cisplatin N/A
Recruiting NCT03480971 - Treatment of Radiation and Cisplatin Induced Toxicities With Tempol Phase 2
Completed NCT00716976 - Sodium Thiosulfate in Preventing Hearing Loss in Young Patients Receiving Cisplatin for Newly Diagnosed Germ Cell Tumor, Hepatoblastoma, Medulloblastoma, Neuroblastoma, Osteosarcoma, or Other Malignancy Phase 3
Completed NCT01139281 - The Protective Effect of Ginkgo Biloba Extract on Cisplatin-induced Ototoxicity in Humans Phase 2
Enrolling by invitation NCT02819856 - SPI-1005 for Prevention and Treatment of Tobramycin Induced Ototoxicity Phase 2
Terminated NCT04226456 - Intratympanic Administration of N-acetylcysteine for Protection of Cisplatin-induced Ototoxicity Phase 4
Recruiting NCT05641441 - Radiosurgery Induced Ototoxicity in Patients Treated for a Vestibular Schwannoma
Not yet recruiting NCT01285674 - Intratympanic Steroid Treatment For The Prevention Of Inner Ear Toxicity Associated With Systemic Treatment With Cisplatin. N/A
Completed NCT01263262 - A Comparison of Infection Rates Between Two Surgical Sites N/A
Not yet recruiting NCT01451853 - SPI-1005 for Prevention and Treatment of Chemotherapy Induced Hearing Loss Phase 2
Completed NCT04262336 - Study to Evaluate Safety and Efficacy of DB-020 to Protect Hearing in Patients Receiving Cisplatin for Cancer Treatment Phase 1
Not yet recruiting NCT00578760 - Does Aspirin Have a Protective Role Against Chemotherapeutically Induced Ototoxicity? N/A
Completed NCT00652132 - Cisplatin With or Without Sodium Thiosulfate in Treating Young Patients With Stage I, II, or III Childhood Liver Cancer Phase 3
Withdrawn NCT02382068 - Dexamethasone in Preventing Hearing Loss in Patients Receiving Cisplatin N/A
Recruiting NCT01216800 - Intensity-Modulated Radiation Therapy or 3-Dimensional Conformal Radiation Therapy in Decreasing Hearing Loss in Patients Who Have Undergone Surgery for Parotid Tumors Phase 3
Completed NCT01848457 - Preventing Nephrotoxicity and Ototoxicity From Osteosarcoma Therapy Phase 2
Active, not recruiting NCT00683319 - Observing Young Patients With Ependymoma Undergoing Standard Combination Chemotherapy Phase 3